SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA

Clinical trials for SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA trials appear

Sign up with your email to follow new studies for SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New hope for rare, aggressive kidney cancer after other treatments fail

Disease control Not yet recruiting

This study is testing whether a new drug called sacituzumab tirumotecan can help control an advanced and aggressive form of kidney cancer called SMARCB1-deficient renal medullary carcinoma. It is for adult patients whose cancer has continued to grow despite receiving at least one…

Matched conditions: SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA

Get alerted when new SMARCB1-DEFICIENT RENAL MEDULLARY CARCINOMA trials appear

New hope for rare, aggressive kidney cancer after other treatments fail